Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615171 | 0.89 | HTR1F (0.41) | PIK3C3HTR1FNPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL615236 | 0.88 | HTR1F (0.40) | PIK3C3HTR1FNPC1RAB9AMAPT | |
| SCHEMBL616313 | 0.85 | STIM1 (0.43) | MALT1NPC1RAB9AIL2 | |
| SCHEMBL1782601 | 0.85 | TP53 (0.40) | HTR1FMALT1NPC1RAB9ATP53 | |
| SCHEMBL1780778 | 0.84 | SMN1; SMN2 (0.41) | MALT1NPC1RAB9AGSK3BDYRK1A | |
| SCHEMBL1784219 | 0.84 | STIM1 (0.39) | MALT1NPC1RAB9AIL2TP53 | |
| SCHEMBL1780500 | 0.83 | HTR1F (0.40) | PIK3C3HTR1FNPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL3827236 | 0.83 | HTR1F (0.40) | PIK3C3HTR1FNPC1RAB9AMAPT | |
| SCHEMBL1783798 | 0.82 | IL2 (0.43) | NPC1RAB9AIL2TP53THRB | |
| SCHEMBL1782706 | 0.82 | IL2 (0.41) | IL2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338163-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHAMACEUTICALS CORP. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| EP-2185514-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009017831-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017831-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | PIK3C3 1720/4885HTR1F 3986/4885MALT1 197/4885 |
| US-20130338163-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | PIK3C3 1437/4885HTR1F 3138/4885MALT1 1/4885 |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | PIK3C3 1437/4885HTR1F 3138/4885MALT1 1/4885 |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | PIK3C3 1437/4885HTR1F 3138/4885MALT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.